Coexpression cluster:C3732: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{ | |||
Latest revision as of 12:32, 17 September 2013
Full id: C3732_migratory_immature_CD14_Astrocyte_papillotubular_clear_mycosis
Phase1 CAGE Peaks
Hg19::chr18:56338688..56338708,+ | p1@MALT1 |
Hg19::chr1:995067..995099,+ | p1@uc009vjs.1 |
Hg19::chr1:995102..995125,+ | p1@ENST00000427998 p1@uc001acl.1 |
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
No results for this coexpression
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0032449 | CBM complex | 0.00240315553985635 |
GO:0002711 | positive regulation of T cell mediated immunity | 0.00240315553985635 |
GO:0032743 | positive regulation of interleukin-2 production | 0.00240315553985635 |
GO:0002726 | positive regulation of T cell cytokine production | 0.00240315553985635 |
GO:0002369 | T cell cytokine production | 0.00240315553985635 |
GO:0002724 | regulation of T cell cytokine production | 0.00240315553985635 |
GO:0002702 | positive regulation of production of molecular mediator of immune response | 0.00240315553985635 |
GO:0002720 | positive regulation of cytokine production during immune response | 0.00240315553985635 |
GO:0002709 | regulation of T cell mediated immunity | 0.00240315553985635 |
GO:0032663 | regulation of interleukin-2 production | 0.00240315553985635 |
GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.00240315553985635 |
GO:0002718 | regulation of cytokine production during immune response | 0.00240315553985635 |
GO:0002821 | positive regulation of adaptive immune response | 0.00240315553985635 |
GO:0002700 | regulation of production of molecular mediator of immune response | 0.00240315553985635 |
GO:0002367 | cytokine production during immune response | 0.00240315553985635 |
GO:0043621 | protein self-association | 0.00240315553985635 |
GO:0002705 | positive regulation of leukocyte mediated immunity | 0.00240315553985635 |
GO:0002456 | T cell mediated immunity | 0.00240315553985635 |
GO:0002708 | positive regulation of lymphocyte mediated immunity | 0.00240315553985635 |
GO:0002699 | positive regulation of immune effector process | 0.00240315553985635 |
GO:0007250 | activation of NF-kappaB-inducing kinase | 0.00240315553985635 |
GO:0002703 | regulation of leukocyte mediated immunity | 0.00240315553985635 |
GO:0002706 | regulation of lymphocyte mediated immunity | 0.00240315553985635 |
GO:0002819 | regulation of adaptive immune response | 0.00240315553985635 |
GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains. | 0.00240315553985635 |
GO:0002697 | regulation of immune effector process | 0.00266622286226666 |
GO:0050852 | T cell receptor signaling pathway | 0.00290980371635028 |
GO:0019209 | kinase activator activity | 0.00297093404652571 |
GO:0032623 | interleukin-2 production | 0.0033465693857416 |
GO:0001819 | positive regulation of cytokine production | 0.0035431139369677 |
GO:0002440 | production of molecular mediator of immune response | 0.00389935093606499 |
GO:0050851 | antigen receptor-mediated signaling pathway | 0.00389935093606499 |
GO:0002429 | immune response-activating cell surface receptor signaling pathway | 0.00420132087387474 |
GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 0.00421367769997437 |
GO:0002757 | immune response-activating signal transduction | 0.00422532842172546 |
GO:0002764 | immune response-regulating signal transduction | 0.00423633188115703 |
GO:0050870 | positive regulation of T cell activation | 0.00498630451083555 |
GO:0001817 | regulation of cytokine production | 0.00498630451083555 |
GO:0051168 | nuclear export | 0.00521394693065481 |
GO:0030693 | caspase activity | 0.00574863661035056 |
GO:0051251 | positive regulation of lymphocyte activation | 0.00574863661035056 |
GO:0050863 | regulation of T cell activation | 0.00649204106463026 |
GO:0051259 | protein oligomerization | 0.00666349031623854 |
GO:0032147 | activation of protein kinase activity | 0.00716796785828425 |
GO:0002253 | activation of immune response | 0.00716796785828425 |
GO:0002449 | lymphocyte mediated immunity | 0.00716796785828425 |
GO:0002250 | adaptive immune response | 0.00716796785828425 |
GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.00716796785828425 |
GO:0051249 | regulation of lymphocyte activation | 0.00716796785828425 |
GO:0002443 | leukocyte mediated immunity | 0.00720946661956905 |
GO:0050865 | regulation of cell activation | 0.00724933797845053 |
GO:0050778 | positive regulation of immune response | 0.00749896140884057 |
GO:0002684 | positive regulation of immune system process | 0.00749896140884057 |
GO:0050776 | regulation of immune response | 0.00810781221274073 |
GO:0042110 | T cell activation | 0.00810781221274073 |
GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB cascade | 0.00810781221274073 |
GO:0002682 | regulation of immune system process | 0.00810781221274073 |
GO:0051240 | positive regulation of multicellular organismal process | 0.00836642346435401 |
GO:0043122 | regulation of I-kappaB kinase/NF-kappaB cascade | 0.00845960881044609 |
GO:0002252 | immune effector process | 0.00847266376231406 |
GO:0001816 | cytokine production | 0.00856105220692837 |
GO:0019207 | kinase regulator activity | 0.00909382679474178 |
GO:0007249 | I-kappaB kinase/NF-kappaB cascade | 0.0100831700972994 |
GO:0045860 | positive regulation of protein kinase activity | 0.0100831700972994 |
GO:0004197 | cysteine-type endopeptidase activity | 0.0100831700972994 |
GO:0033674 | positive regulation of kinase activity | 0.0100831700972994 |
GO:0051347 | positive regulation of transferase activity | 0.010139605750829 |
GO:0009967 | positive regulation of signal transduction | 0.0101541783374212 |
GO:0006913 | nucleocytoplasmic transport | 0.0101541783374212 |
GO:0046649 | lymphocyte activation | 0.0101541783374212 |
GO:0051169 | nuclear transport | 0.0101541783374212 |
GO:0004842 | ubiquitin-protein ligase activity | 0.0105090574187607 |
GO:0008639 | small protein conjugating enzyme activity | 0.0105090574187607 |
GO:0006916 | anti-apoptosis | 0.0106168513974943 |
GO:0045321 | leukocyte activation | 0.0110914871070293 |
GO:0001775 | cell activation | 0.0127089956434711 |
GO:0043066 | negative regulation of apoptosis | 0.0136242834052795 |
GO:0043069 | negative regulation of programmed cell death | 0.0136273612960296 |
GO:0045859 | regulation of protein kinase activity | 0.0138073039089563 |
GO:0019787 | small conjugating protein ligase activity | 0.0138073039089563 |
GO:0043549 | regulation of kinase activity | 0.0138073039089563 |
GO:0051338 | regulation of transferase activity | 0.0139207180662411 |
GO:0043085 | positive regulation of catalytic activity | 0.0142541199769051 |
GO:0051239 | regulation of multicellular organismal process | 0.0152397913127337 |
GO:0008234 | cysteine-type peptidase activity | 0.0160676097141558 |
GO:0016881 | acid-amino acid ligase activity | 0.0160676097141558 |
GO:0006461 | protein complex assembly | 0.0180608506532087 |
GO:0016879 | ligase activity, forming carbon-nitrogen bonds | 0.0194836255525941 |
GO:0007243 | protein kinase cascade | 0.0195243406003887 |
GO:0008047 | enzyme activator activity | 0.0233640121930479 |
GO:0006512 | ubiquitin cycle | 0.0278810733597028 |
GO:0042981 | regulation of apoptosis | 0.0286231925342692 |
GO:0043067 | regulation of programmed cell death | 0.0286231925342692 |
GO:0006952 | defense response | 0.0287120056316716 |
GO:0050790 | regulation of catalytic activity | 0.0294313583322489 |
GO:0016874 | ligase activity | 0.0311466673535068 |
GO:0065009 | regulation of a molecular function | 0.0319690199691438 |
GO:0065003 | macromolecular complex assembly | 0.0356512085583085 |
GO:0009966 | regulation of signal transduction | 0.0371102672789356 |
GO:0004175 | endopeptidase activity | 0.0371102672789356 |
GO:0022607 | cellular component assembly | 0.0372004084901602 |
GO:0006915 | apoptosis | 0.038676625753476 |
GO:0012501 | programmed cell death | 0.038676625753476 |
GO:0008219 | cell death | 0.0396747376863077 |
GO:0016265 | death | 0.0396747376863077 |
GO:0046907 | intracellular transport | 0.0396747376863077 |
GO:0048522 | positive regulation of cellular process | 0.0412043563088239 |
GO:0048518 | positive regulation of biological process | 0.0454442874524118 |
GO:0051649 | establishment of cellular localization | 0.0465537188207882 |
GO:0051641 | cellular localization | 0.0473068730398296 |
GO:0048523 | negative regulation of cellular process | 0.0473386668194157 |
GO:0048519 | negative regulation of biological process | 0.0486275006277944 |
GO:0006955 | immune response | 0.0486275006277944 |
GO:0008233 | peptidase activity | 0.0499116919816319 |
GO:0048468 | cell development | 0.0499116919816319 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
classical monocyte | 2.14e-17 | 42 |
CD14-positive, CD16-negative classical monocyte | 2.14e-17 | 42 |
defensive cell | 4.58e-17 | 48 |
phagocyte | 4.58e-17 | 48 |
granulocyte monocyte progenitor cell | 3.52e-16 | 67 |
macrophage dendritic cell progenitor | 1.49e-14 | 61 |
monopoietic cell | 1.89e-13 | 59 |
monocyte | 1.89e-13 | 59 |
monoblast | 1.89e-13 | 59 |
promonocyte | 1.89e-13 | 59 |
myeloid lineage restricted progenitor cell | 2.62e-13 | 66 |
myeloid leukocyte | 7.07e-13 | 72 |
epithelial cell | 1.75e-10 | 253 |
leukocyte | 1.35e-09 | 136 |
hematopoietic lineage restricted progenitor cell | 3.52e-09 | 120 |
myeloid cell | 1.73e-08 | 108 |
common myeloid progenitor | 1.73e-08 | 108 |
kidney cell | 2.39e-08 | 17 |
kidney epithelial cell | 2.39e-08 | 17 |
nongranular leukocyte | 4.76e-08 | 115 |
epithelial cell of nephron | 2.20e-07 | 15 |
kidney tubule cell | 5.73e-07 | 10 |
nephron tubule epithelial cell | 5.73e-07 | 10 |
Ontology term | p-value | n |
---|---|---|
skeletal element | 3.33e-12 | 90 |
bone element | 4.09e-12 | 82 |
bone marrow | 2.12e-11 | 76 |
skeletal system | 8.37e-10 | 100 |
immune system | 1.73e-09 | 93 |
hematopoietic system | 1.12e-08 | 98 |
blood island | 1.12e-08 | 98 |
hemolymphoid system | 1.21e-07 | 108 |
nephron epithelium | 2.20e-07 | 15 |
renal tubule | 2.20e-07 | 15 |
nephron tubule | 2.20e-07 | 15 |
nephron | 2.20e-07 | 15 |
uriniferous tubule | 2.20e-07 | 15 |
nephrogenic mesenchyme | 2.20e-07 | 15 |
organ | 4.46e-07 | 503 |
excretory tube | 4.79e-07 | 16 |
kidney epithelium | 4.79e-07 | 16 |
nephron tubule epithelium | 5.73e-07 | 10 |
Ontology term | p-value | n |
---|---|---|
carcinoma | 1.15e-11 | 106 |
cell type cancer | 1.08e-10 | 143 |
cancer | 2.93e-08 | 235 |
disease of cellular proliferation | 3.39e-08 | 239 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
MA0003.1 | 6.06693 |
MA0004.1 | 0.826076 |
MA0006.1 | 0.639288 |
MA0007.1 | 0.804807 |
MA0009.1 | 1.3275 |
MA0014.1 | 4.7105 |
MA0017.1 | 0.686276 |
MA0019.1 | 0.990656 |
MA0024.1 | 1.21731 |
MA0025.1 | 1.46617 |
MA0027.1 | 2.95767 |
MA0028.1 | 0.658629 |
MA0029.1 | 1.23771 |
MA0030.1 | 1.22561 |
MA0031.1 | 1.15713 |
MA0038.1 | 0.94098 |
MA0040.1 | 1.24388 |
MA0041.1 | 0.847069 |
MA0042.1 | 0.810843 |
MA0043.1 | 1.32783 |
MA0046.1 | 1.31611 |
MA0048.1 | 0.341392 |
MA0050.1 | 0.81185 |
MA0051.1 | 0.936307 |
MA0052.1 | 1.24796 |
MA0055.1 | 0.190716 |
MA0056.1 | 0 |
MA0057.1 | 0.333427 |
MA0058.1 | 0.716037 |
MA0059.1 | 0.714521 |
MA0060.1 | 0.492218 |
MA0061.1 | 0.456531 |
MA0063.1 | 0 |
MA0066.1 | 0.941452 |
MA0067.1 | 1.65513 |
MA0068.1 | 0.405474 |
MA0069.1 | 1.31207 |
MA0070.1 | 1.30033 |
MA0071.1 | 0.897953 |
MA0072.1 | 1.29561 |
MA0073.1 | 0.0834661 |
MA0074.1 | 0.935474 |
MA0076.1 | 0.734647 |
MA0077.1 | 1.28751 |
MA0078.1 | 1.04495 |
MA0081.1 | 0.714712 |
MA0083.1 | 1.33535 |
MA0084.1 | 1.84562 |
MA0087.1 | 1.29304 |
MA0088.1 | 2.03569 |
MA0089.1 | 0 |
MA0090.1 | 0.751469 |
MA0091.1 | 0.829044 |
MA0092.1 | 0.785956 |
MA0093.1 | 0.642957 |
MA0095.1 | 0 |
MA0098.1 | 0 |
MA0100.1 | 0.956299 |
MA0101.1 | 0.646932 |
MA0103.1 | 0.628063 |
MA0105.1 | 0.846801 |
MA0106.1 | 0.986396 |
MA0107.1 | 0.556367 |
MA0108.2 | 1.15387 |
MA0109.1 | 0 |
MA0111.1 | 0.767139 |
MA0113.1 | 1.00436 |
MA0114.1 | 0.549955 |
MA0115.1 | 1.57693 |
MA0116.1 | 0.560723 |
MA0117.1 | 1.36676 |
MA0119.1 | 0.695578 |
MA0122.1 | 1.39371 |
MA0124.1 | 1.53432 |
MA0125.1 | 1.44766 |
MA0130.1 | 0 |
MA0131.1 | 2.4174 |
MA0132.1 | 0 |
MA0133.1 | 0 |
MA0135.1 | 1.35921 |
MA0136.1 | 0.948776 |
MA0139.1 | 0.440097 |
MA0140.1 | 0.894983 |
MA0141.1 | 0.712476 |
MA0142.1 | 1.12317 |
MA0143.1 | 1.00455 |
MA0144.1 | 0.531867 |
MA0145.1 | 0.273764 |
MA0146.1 | 3.00132 |
MA0147.1 | 0.565108 |
MA0148.1 | 0.854239 |
MA0149.1 | 0.884158 |
MA0062.2 | 1.141 |
MA0035.2 | 0.894194 |
MA0039.2 | 8.82315 |
MA0138.2 | 1.04628 |
MA0002.2 | 0.476938 |
MA0137.2 | 0.666381 |
MA0104.2 | 0.491226 |
MA0047.2 | 0.973066 |
MA0112.2 | 2.07067 |
MA0065.2 | 0.277623 |
MA0150.1 | 0.744617 |
MA0151.1 | 0 |
MA0152.1 | 0.902317 |
MA0153.1 | 1.43021 |
MA0154.1 | 0.312019 |
MA0155.1 | 1.31345 |
MA0156.1 | 0.669101 |
MA0157.1 | 1.09377 |
MA0158.1 | 0 |
MA0159.1 | 0.565904 |
MA0160.1 | 0.871361 |
MA0161.1 | 0 |
MA0162.1 | 2.05956 |
MA0163.1 | 1.2663 |
MA0164.1 | 1.01792 |
MA0080.2 | 0.643061 |
MA0018.2 | 0.987913 |
MA0099.2 | 0.902716 |
MA0079.2 | 2.28794 |
MA0102.2 | 1.88331 |
MA0258.1 | 1.29138 |
MA0259.1 | 2.40872 |
MA0442.1 | 0 |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)
TF | #promoters | Enrichment | p-value | q-value |
---|---|---|---|---|
CTCFL#140690 | 2 | 13.1643162393162 | 0.00743336703699601 | 0.0306790523602777 |
E2F6#1876 | 3 | 5.01715573169739 | 0.0079176980688633 | 0.0322020510383587 |
ELF1#1997 | 3 | 4.25809795880754 | 0.0129517987505461 | 0.0462057356006245 |
TFAP2A#7020 | 2 | 11.0124229153633 | 0.0105499065521556 | 0.0390122044542217 |
TFAP2C#7022 | 3 | 10.8092286098602 | 0.000791674657575313 | 0.00615741060191452 |
THAP1#55145 | 2 | 20.9127630685675 | 0.00298344741373694 | 0.0158665986578711 |
ZEB1#6935 | 2 | 11.2589546783626 | 0.0101022267664633 | 0.0378132915655745 |
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.